Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Fundamental Analysis

NASDAQ:XENE - Nasdaq - CA98420N1050 - Common Stock - Currency: USD

29.57  -0.17 (-0.57%)

After market: 29.57 0 (0%)

Fundamental Rating

3

Overall XENE gets a fundamental rating of 3 out of 10. We evaluated XENE against 562 industry peers in the Biotechnology industry. XENE has a great financial health rating, but its profitability evaluates not so good. XENE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XENE had negative earnings in the past year.
XENE had a negative operating cash flow in the past year.
In the past 5 years XENE always reported negative net income.
In the past 5 years XENE always reported negative operating cash flow.
XENE Yearly Net Income VS EBIT VS OCF VS FCFXENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

XENE's Return On Assets of -22.52% is fine compared to the rest of the industry. XENE outperforms 76.69% of its industry peers.
XENE's Return On Equity of -23.58% is amongst the best of the industry. XENE outperforms 83.81% of its industry peers.
Industry RankSector Rank
ROA -22.52%
ROE -23.58%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
XENE Yearly ROA, ROE, ROICXENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XENE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENE Yearly Profit, Operating, Gross MarginsXENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

XENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XENE has more shares outstanding
Compared to 5 years ago, XENE has more shares outstanding
There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XENE Yearly Shares OutstandingXENE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XENE Yearly Total Debt VS Total AssetsXENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

XENE has an Altman-Z score of 33.04. This indicates that XENE is financially healthy and has little risk of bankruptcy at the moment.
XENE has a Altman-Z score of 33.04. This is amongst the best in the industry. XENE outperforms 97.69% of its industry peers.
There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.04
ROIC/WACCN/A
WACC8.55%
XENE Yearly LT Debt VS Equity VS FCFXENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 23.27 indicates that XENE has no problem at all paying its short term obligations.
With an excellent Current ratio value of 23.27, XENE belongs to the best of the industry, outperforming 96.62% of the companies in the same industry.
XENE has a Quick Ratio of 23.27. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 23.27, XENE belongs to the top of the industry, outperforming 96.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 23.27
Quick Ratio 23.27
XENE Yearly Current Assets VS Current LiabilitesXENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for XENE have decreased strongly by -19.19% in the last year.
EPS 1Y (TTM)-19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.40% on average over the next years. This is quite good.
The Revenue is expected to grow by 378.32% on average over the next years. This is a very strong growth
EPS Next Y-37.4%
EPS Next 2Y-23.39%
EPS Next 3Y-9.92%
EPS Next 5Y15.4%
Revenue Next Year534.66%
Revenue Next 2Y924.37%
Revenue Next 3Y673.32%
Revenue Next 5Y378.32%

3.3 Evolution

XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XENE. In the last year negative earnings were reported.
Also next year XENE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENE Price Earnings VS Forward Price EarningsXENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XENE Per share dataXENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as XENE's earnings are expected to decrease with -9.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.39%
EPS Next 3Y-9.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XENE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XENON PHARMACEUTICALS INC

NASDAQ:XENE (5/15/2025, 4:43:11 PM)

After market: 29.57 0 (0%)

29.57

-0.17 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners101.8%
Inst Owner Change-0.45%
Ins Owners0.12%
Ins Owner Change0%
Market Cap2.26B
Analysts87.83
Price Target57.2 (93.44%)
Short Float %4.78%
Short Ratio4.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.69%
Min EPS beat(2)-5.1%
Max EPS beat(2)8.49%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-5.1%
Max EPS beat(4)17.35%
EPS beat(8)5
Avg EPS beat(8)3%
EPS beat(12)7
Avg EPS beat(12)0.73%
EPS beat(16)9
Avg EPS beat(16)-2.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.05%
PT rev (3m)-1.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-64.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.68
P/tB 2.68
EV/EBITDA N/A
EPS(TTM)-3.23
EYN/A
EPS(NY)-4.6
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS11.02
TBVpS11.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.52%
ROE -23.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.27
Quick Ratio 23.27
Altman-Z 33.04
F-Score2
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)190.35%
Cap/Depr(5y)241.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.87%
EPS Next Y-37.4%
EPS Next 2Y-23.39%
EPS Next 3Y-9.92%
EPS Next 5Y15.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year534.66%
Revenue Next 2Y924.37%
Revenue Next 3Y673.32%
Revenue Next 5Y378.32%
EBIT growth 1Y-27.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.24%
EBIT Next 3Y-5.16%
EBIT Next 5Y12.24%
FCF growth 1Y-14.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.43%
OCF growth 3YN/A
OCF growth 5YN/A